{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T23:29:29Z","timestamp":1786318169203,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Individuals carrying ultra-rare CFTR variants remain untreated with CFTR modulator therapies due to a lack of functional and clinical data supporting variant-specific responsiveness. This study aimed to functionally characterize two ultra-rare CFTR variants, p.Glu1104Lys (E1104K) and p.Leu999del (L999del), each found\n                      <jats:italic>in trans<\/jats:italic>\n                      with the minimal function variant G542X, and to evaluate their responsiveness to the triple-combination regimens elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) and vanzacaftor\/tezacaftor\/ivacaftor (VAN\/TEZ\/IVA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patient-derived intestinal organoids (PDIOs) of two people with cystic fibrosis (G542X\/E1104K and G542X\/L999del) were cultured from rectal biopsies and subjected to forskolin-induced swelling (FIS) assays. CFTR function was quantified by calculating the area under the curve after 60\u2009minutes. Human nasal epithelial cells (HNECs) were obtained by nasal brushing, expanded under air\u2013liquid interface conditions, and evaluated in Ussing chambers. CFTRinh-172-sensitive stimulated currents (\u0394CFTRinh-172 I\n                      <jats:sub>SC<\/jats:sub>\n                      ) were expressed as percentages of the mean response of healthy controls. Both PDIOs exhibited visible swelling under untreated conditions, indicating residual CFTR function. Following pretreatment with ELX\/TEZ or VAN\/TEZ, both showed marked pre-swelling limiting quantitative analysis to qualitative assessment. In HNECs, residual CFTR activity reached 15% and 13% of WT levels for E1104K and L999del, respectively. Upon modulator treatment, CFTR activity increased to 90% (ELX\/TEZ) and 97% (VAN\/TEZ) in E1104K, and to 46% and 56% in L999del.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>E1104K and L999del exhibit measurable residual CFTR function and in vitro responsiveness to two CFTRm triple-combination regimens. These findings support theranostic approaches to guide therapy in individuals with ultra-rare CFTR genotypes, while clinical use remains dependent on regulatory approval and individualized patient assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04415-1","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:13:52Z","timestamp":1780438432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of two ultra-rare CFTR variants, P.Leu999del and P.Glu1104Lys, with unknown theratyping profiles"],"prefix":"10.1186","volume":"21","author":[{"given":"Tereza","family":"Dousova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-1302","authenticated-orcid":false,"given":"Lucie","family":"Borek-Dohalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stepanka","family":"Novotna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Skalicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Libik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Milan","family":"Macek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Drevinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"1","key":"4415_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen L, Allen L, Carr SB, Davies G, Downey D, Egan M, et al. Future therapies for cystic fibrosis. Nat Commun. 2023, Feb, 8;14(1):693. https:\/\/doi.org\/10.1038\/s41467-023-36244-2.","journal-title":"Nat Commun"},{"issue":"10408","key":"4415_CR2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","volume":"402","author":"JL Taylor-Cousar","year":"2023","unstructured":"Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023;402(10408):1171\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(23)01609-4.","journal-title":"Lancet"},{"issue":"19","key":"4415_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1908639.","journal-title":"N Engl J Med"},{"issue":"2","key":"4415_CR4","doi-asserted-by":"publisher","first-page":"2301008","DOI":"10.1183\/13993003.01008-2023","volume":"62","author":"MM Tunney","year":"2023","unstructured":"Tunney MM, Wark P. Long-term therapy with elexacaftor\/tezacaftor\/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist. Eur Respir J. 2023;62(2):2301008. https:\/\/doi.org\/10.1183\/13993003.01008-2023.","journal-title":"Eur Respir J"},{"key":"4415_CR5","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information: elexacaftor\/tezacaftor\/ivacaftor. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212273s015lbl.pdf. 15 January 2026."},{"key":"4415_CR6","unstructured":"European Medicines Agency. Kaftrio: EPAR - Assessment report (variation). 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/kaftrio-h-c-005269-ws-2551-epar-assessment-report-variation_en.pdf. 15 January 2026."},{"key":"4415_CR7","unstructured":"European Medicines Agency. Combination of cystic fibrosis medicines to treat patients with rare mutations. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/news\/combination-cystic-fibrosis-medicines-treat-patients-rare-mutations. 15 January 2026."},{"key":"4415_CR8","unstructured":"U.S. Food and Drug Administration. Drug trials snapshot: ALYFTREK (vanzacaftor\/tezacaftor\/deutivacaftor). 2025. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-alyftrek. 15 January 2026."},{"key":"4415_CR9","unstructured":"European Medicines Agency. Meeting highlights from the committee for medicinal products for human use (CHMP). 2025. Available from: April 22\u201325. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2025. 15 January 2026."},{"key":"4415_CR10","unstructured":"UK Medicines and Healthcare products Regulatory Agency. Triple combination medicine deutivacaftor\/tezacaftor\/vanzacaftor approved for cystic fibrosis. 2025. Available from: https:\/\/www.gov.uk\/government\/news\/triple-combination-medicine-deutivacaftortezacaftorvanzacaftor-approved-for-cystic-fibrosis. 15 January 2026."},{"issue":"3","key":"4415_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","volume":"13","author":"C Keating","year":"2025","unstructured":"Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, et al. Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. LancetThe Lancet Respir Med. 2025;13(3):256\u201371. https:\/\/doi.org\/10.1016\/S2213-2600(24)00411-9.","journal-title":"LancetThe Lancet Respir Med"},{"issue":"3","key":"4415_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jcf.2021.10.011","volume":"21","author":"KS Raraigh","year":"2022","unstructured":"Raraigh KS, Aksit MA, Hetrick K, Pace RG, Ling H, O\u2019Neal W, et al. Complete CFTR gene sequencing in 5, 058 individuals with cystic fibrosis informs variant-specific treatment. J Educ Chang Cyst Fibros. 2022;21(3):463\u201370. https:\/\/doi.org\/10.1016\/j.jcf.2021.10.011.","journal-title":"J Educ Chang Cyst Fibros"},{"key":"4415_CR13","unstructured":"Cystic Fibrosis Mutation Database. CFTR mutation database. 2025. Available from: http:\/\/www.genet.sickkids.on.ca\/. 15 January 2026."},{"key":"4415_CR14","unstructured":"CFTR2, Clinical and Functional Translation of CFTR. 2025. Available from: https:\/\/cftr2.org\/. 15 January 2026."},{"key":"4415_CR15","unstructured":"C-F. French CFTR database. 2025. Available from: https:\/\/cftr.chu-montpellier.fr\/cgi-bin\/home.cgi. 15 January 2026."},{"issue":"4","key":"4415_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","volume":"23","author":"H Bihler","year":"2024","unstructured":"Bihler H, Sivachenko A, Millen L, Bhatt P, Patel AT, Chin J, et al. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis. J Educ Chang Cyst Fibros. 2024;23(4):664\u201375. https:\/\/doi.org\/10.1016\/j.jcf.2024.02.006.","journal-title":"J Educ Chang Cyst Fibros"},{"issue":"4","key":"4415_CR17","doi-asserted-by":"publisher","first-page":"2400156","DOI":"10.1183\/13993003.00156-2024","volume":"63","author":"E Furstova","year":"2024","unstructured":"Furstova E, Drevinek P, Novotna S, Libik M, Benesova K, Borek-Dohalska L, et al. Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay. Eur Respir J. 2024;63(4):2400156. https:\/\/doi.org\/10.1183\/13993003.00156-2024.","journal-title":"Eur Respir J"},{"issue":"2","key":"4415_CR18","doi-asserted-by":"publisher","first-page":"101419","DOI":"10.1016\/j.xpro.2022.101419","volume":"3","author":"A Golec","year":"2022","unstructured":"Golec A, Pranke I, Scudieri P, Hayes K, Dreano E, Dunlevy F, et al. Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants. Star Protoc. 2022;3(2):101419. https:\/\/doi.org\/10.1016\/j.xpro.2022.101419.","journal-title":"Star Protoc"},{"key":"4415_CR19","unstructured":"National Center for Biotechnology Information. ClinVar: public archive of relationships among sequence variation and human phenotype. 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/. 15 January 2026."},{"key":"4415_CR20","doi-asserted-by":"publisher","unstructured":"Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886\u201394. https:\/\/doi.org\/10.1093\/nar\/gky1016.","DOI":"10.1093\/nar\/gky1016"},{"key":"4415_CR21","unstructured":"REVEL. Rare Exome Variant Ensemble Learner. 2025. Available from: https:\/\/sites.google.com\/site\/revelgenomics. 15 January 2026."},{"key":"4415_CR22","doi-asserted-by":"publisher","unstructured":"Harrison SM, Biesecker LG, Rehm HL. Overview of specifications to the ACMG\/AMP variant interpretation guidelines. CP Hum Genet. 2019;103(1):e93. https:\/\/doi.org\/10.1002\/cphg.93.","DOI":"10.1002\/cphg.93"},{"key":"4415_CR23","doi-asserted-by":"publisher","unstructured":"McDonald EF, Oliver KE, Schlebach JP, Meiler J, Plate L. Benchmarking AlphaMissense pathogenicity predictions against cystic fibrosis variants. PLoS One. 2024;19(1):e0297560. https:\/\/doi.org\/10.1371\/journal.pone.0297560.","DOI":"10.1371\/journal.pone.0297560"},{"key":"4415_CR24","unstructured":"Genome aggregation database (gnomAD). gnomAD browser. 2025. Available from: https:\/\/gnomad.broadinstitute.org\/. 15 January 2026."},{"key":"4415_CR25","doi-asserted-by":"publisher","first-page":"1155705","DOI":"10.3389\/fmolb.2023.1155705","volume":"10","author":"V Railean","year":"2023","unstructured":"Railean V, Rodrigues CS, Ramalho SS, Silva IAL, Bartosch J, Farinha CM, et al. Personalized medicine: function of CFTR variant p.Arg334Trp is rescued by currently available CFTR modulators. Front Mol Biosci. 2023;10:1155705. https:\/\/doi.org\/10.3389\/fmolb.2023.1155705.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"4415_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jcf.2024.04.014","volume":"23","author":"MC Bierlaagh","year":"2024","unstructured":"Bierlaagh MC, Ramalho AS, Silva IAL, Vonk AM, van den Bor RM, van Mourik P, et al. Repeatability and reproducibility of the forskolin-induced swelling (FIS) assay on intestinal organoids from people with cystic fibrosis. J Educ Chang Cyst Fibros. 2024;23(4):693\u2013702. https:\/\/doi.org\/10.1016\/j.jcf.2024.04.014.","journal-title":"J Educ Chang Cyst Fibros"},{"key":"4415_CR27","doi-asserted-by":"publisher","unstructured":"Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016, 22;8(344):344ra84. https:\/\/doi.org\/10.1126\/scitranslmed.aad8278.","DOI":"10.1126\/scitranslmed.aad8278"},{"issue":"19","key":"4415_CR28","doi-asserted-by":"publisher","first-page":"14539","DOI":"10.3390\/ijms241914539","volume":"24","author":"JW Lefferts","year":"2023","unstructured":"Lefferts JW, Bierlaagh MC, Kroes S, Nieuwenhuijze NDA, Sonneveld van Kooten HN, Niem\u00f6ller PJ, et al. CFTR function restoration upon Elexacaftor\/Tezacaftor\/Ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes. IJMS. 2023;24(19):14539. https:\/\/doi.org\/10.3390\/ijms241914539.","journal-title":"IJMS"},{"issue":"1","key":"4415_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jcf.2024.09.019","volume":"24","author":"S Kroes","year":"2025","unstructured":"Kroes S, Bierlaagh MC, Lefferts JW, Boni A, Muilwijk D, Viscomi C, et al. Elexacaftor\/Tezacaftor\/Ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls. J Educ Chang Cyst Fibros. 2025;24(1):175\u201382. https:\/\/doi.org\/10.1016\/j.jcf.2024.09.019.","journal-title":"J Educ Chang Cyst Fibros"},{"issue":"4","key":"4415_CR30","doi-asserted-by":"publisher","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","volume":"62","author":"E Dreano","year":"2023","unstructured":"Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, et al. Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription. Eur Respir J. 2023;62(4):2300110. https:\/\/doi.org\/10.1183\/13993003.00110-2023.","journal-title":"Eur Respir J"},{"issue":"5","key":"4415_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1165\/rcmb.2023-0398OC","volume":"71","author":"A Pion","year":"2024","unstructured":"Pion A, Kavanagh E, Joynt AT, Raraigh KS, Vanscoy L, Langfelder-Schwind E, et al. Investigation of CFTR function in human nasal epithelial cells informs Personalized medicine. Am J Respir Cell Mol Biol. 2024;71(5):577\u201388. https:\/\/doi.org\/10.1165\/rcmb.2023-0398OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"4415_CR32","doi-asserted-by":"publisher","first-page":"2301959","DOI":"10.1183\/13993003.01959-2023","volume":"63","author":"PR Burgel","year":"2024","unstructured":"Burgel PR, Sermet-Gaudelus I, Girodon E, Kanaan R, Le Bihan J, Remus N, et al. Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint. Eur Respir J. 2024;63(1):2301959. https:\/\/doi.org\/10.1183\/13993003.01959-2023.","journal-title":"Eur Respir J"},{"issue":"1","key":"4415_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcf.2024.09.013","volume":"24","author":"MD Amaral","year":"2025","unstructured":"Amaral MD, Pankonien I. Theranostics vs theratyping or theranostics plus theratyping? J Educ Chang Cyst Fibros. 2025;24(1):10\u201315. https:\/\/doi.org\/10.1016\/j.jcf.2024.09.013.","journal-title":"J Educ Chang Cyst Fibros"},{"issue":"5","key":"4415_CR34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jcf.2015.01.005","volume":"14","author":"EF McKone","year":"2015","unstructured":"McKone EF, Velentgas P, Swenson AJ, Goss CH. Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype. J Educ Chang Cyst Fibros. 2015;14(5):580\u201386. https:\/\/doi.org\/10.1016\/j.jcf.2015.01.005.","journal-title":"J Educ Chang Cyst Fibros"},{"issue":"10448","key":"4415_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","volume":"404","author":"I Sermet-Gaudelus","year":"2024","unstructured":"Sermet-Gaudelus I, Benaboud S, Bui S, Bihou\u00e9e T, Gautier S, Barboura M, et al. Behavioural and sleep issues after initiation of elexacaftor\u2013tezacaftor\u2013ivacaftor in preschool-age children with cystic fibrosis. Lancet. 2024;404(10448):117\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(24)01134-6.","journal-title":"Lancet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04415-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T23:10:11Z","timestamp":1786317011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04415-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4415"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04415-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Motol University Hospital Ethics Committee (reference no.: EK-602.27\/22), and all study subjects and\/or their legal representatives provided informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P. Drevinek, M. Macek, V. Skalicka and T. Dousova report consulting fees and lecture honoraria from Vertex Pharmaceuticals; outside the submitted work. Other authors declare no conflict of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"270"}}